Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The company's financial performance is strong, with a 10% revenue increase, improved gross margin, and significant EPS growth. Despite potential risks, the strategic initiatives and robust financial metrics suggest a positive outlook. The market cap indicates moderate reaction sensitivity, leading to a 'Positive' prediction for the stock price over the next two weeks.
Revenue Revenue for Q1 2026 was $100 million, representing a 10% increase year-over-year, driven by strong demand in the medical and aerospace sectors.
Gross Margin Gross margin improved to 40%, up from 38% in Q1 2025, due to operational efficiencies and favorable product mix.
Operating Income Operating income rose to $20 million, a 15% increase compared to the same period last year, attributed to higher sales and cost management initiatives.
Earnings Per Share (EPS) EPS for the quarter was $1.50, up 25% year-over-year, reflecting improved profitability and share repurchase activities.
EBITDA EBITDA reached $25 million, a 20% increase from Q1 2025, supported by revenue growth and margin expansion.
The selected topic was not discussed during the call.
Forward-looking statements: The company acknowledges that forward-looking statements are subject to risks and uncertainties, which could lead to material differences in actual results compared to expectations.
Risk factors in 10-K: The company refers to risk factors disclosed in its most recent 10-K, which include potential adverse impacts on results due to various factors.
Non-GAAP Financial Measures: During this call, we will discuss non-GAAP financial measures, which include organic sales growth, adjusted gross margin, adjusted operating income, adjusted SG&A, adjusted earnings per share and EBITDA and adjusted EBITDA. A reconciliation of GAAP to non-GAAP measures discussed in this call is contained in the associated press release and is available in the Investor Relations section of our website.
The selected topic was not discussed during the call.
The company's financial performance is strong, with a 10% revenue increase, improved gross margin, and significant EPS growth. Despite potential risks, the strategic initiatives and robust financial metrics suggest a positive outlook. The market cap indicates moderate reaction sensitivity, leading to a 'Positive' prediction for the stock price over the next two weeks.
The earnings call shows strong sales growth and EPS increase, despite some operational inefficiencies. The company has a strategic plan to overcome these inefficiencies and is making progress in its operations. The Q&A reveals management's confidence in handling current challenges and future growth, especially with new programs and partnerships. While there are some uncertainties, such as the AJR backlog and cybersecurity incident, they are being managed effectively. The market cap suggests a moderate reaction, leading to a positive stock price movement prediction.
The earnings call reflects a positive sentiment with key highlights: a 5.1% increase in robotic surgery revenue, strong demand in interventional orthopedics, and successful acquisitions. Despite AJR's labor issues, the company maintains a stable operating margin and continues debt reduction. The Q&A section reveals optimism about future contracts and growth, particularly with Intuitive. Although AJR inefficiencies impact margins, improvements are anticipated. The market cap suggests moderate sensitivity to these developments, leading to a positive stock price prediction.
The earnings call highlights strong revenue growth, especially in the medical business and with key customers like Stryker. Despite labor inefficiencies impacting margins, the company expects recovery by Q4. The Q&A session reveals optimism in robotic surgery opportunities and resolved inventory issues. The strategic expansion in the Dominican Republic and selective M&A activity further support positive sentiment. Given the market cap of $1.98 billion, these factors suggest a positive stock price movement of 2% to 8% over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.